245620 — Eone Diagnomics Genome Center Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Eone Diagnomics Genome Center Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	92,541	89,282	94,244	88,457	30,600
Cost of Revenue
Gross Profit	21,174	9,239	12,769	9,853	5,641
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	98,600	106,765	103,005	110,810	55,130
Operating Profit	-6,059	-17,483	-8,761	-22,353	-24,530
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-8,172	-20,229	-29,789	-34,088	-44,640
Provision for Income Taxes
Net Income After Taxes	-9,433	-20,667	-29,865	-33,027	-45,603
Minority Interest
Net Income Before Extraordinary Items
Net Income	-10,398	-20,667	-29,865	-33,027	-45,603
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-10,398	-20,667	-29,865	-33,027	-45,603
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-103	-196	-302	-276	-275
Dividends per Share